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Retinoid X receptor (RXR) is a nuclear receptor that heterodimerizes with several nuclear
receptors, integrating ligand-mediated signals across the heterodimers. Synthetic RXR
agonists have been developed to cure certain inflammatory diseases, including
inflammatory bowel diseases (IBDs). However, pre-existing RXR agonists, which are
lipophilic and readily absorbed in the upper intestine, cause considerable adverse
effects such as hepatomegaly, hyperlipidemia, and hypothyroidism. To minimize these
adverse effects, we have developed an RXR agonist, NEt-3IB, which has lipophilic and
thus poorly absorptive properties. In this study, we evaluated the effects of NEt-3IB in an
experimental murine colitis model induced through the adoptive transfer of
CD45RBhighCD4+ T cells. Pharmacokinetic studies demonstrated that the major
portion of NEt-3IB was successfully delivered to the large intestine after oral
administration. Notably, NEt-3IB treatment suppressed the development of T cell-
mediated chronic colitis, as indicated by improvement of wasting symptoms,
inflammatory infiltration, and mucosal hyperplasia. The protective effect of NEt-3IB was
mediated by the suppression of IFN-γ-producing Th1 cell expansion in the colon. In
conclusion, NEt-3IB, a large intestine-directed RXR agonist, is a promising drug candidate
for IBDs.
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INTRODUCTION
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is characterized by intermittent
abdominal pain, diarrhea, bodyweight loss, and hematochezia (bloody stools) (Ho and Khalil, 2015).
Although the exact etiology of CD is unknown, genetic variations and immune dysregulation have
been implicated in CD development (De Souza and Fiocchi, 2016). In the gastrointestinal mucosal of
patients with CD, inflammation is prolonged by excessive activation of immune cells such as effector
T cells and inflammatorymacrophages (De Souza and Fiocchi, 2016). For decades, steroids have been
used to cure CD, although long-term treatment with these agents causes considerable adverse effects
such as edema and sleep disturbance (Carter et al., 2004). More recently, biological agents such as
anti-TNF-α antibodies were developed to potently suppress the inflammatory response in CD.
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However, the cost of biological agents is much higher than that of
the classical chemical drugs, and approximately 30% of CD
patients fail to respond to therapy using anti-TNF-α
antibodies (Adegbola et al., 2018). Moreover, half of the
primary responders lose their therapeutic response over time,
thereby facing an increased dosage or a revised therapeutic
strategy (Adegbola et al., 2018). These facts emphasize the
medical need for the development of first-in-class medicines
with high efficacy, low cost, and minimal adverse effects.
Retinoid X receptor (RXR) is a nuclear receptor that
heterodimerizes with other nuclear receptors such as
peroxisome proliferator-activated receptor (PPAR), liver X
receptor (LXR), pregnane X receptor (PXR), and NR4A1
(Nur77) (Evans and Mangelsdorf, 2014). Treatment with an
RXR agonist can activate these partner nuclear receptors
without their own ligand stimulation (Takeuchi et al., 2013;
Evans and Mangelsdorf, 2014), a phenomenon termed the
“permissive effect.” Activation of these nuclear receptors
shows an anti-inflammatory effect, at least partly through
mitigating the proliferation and differentiation of inflammatory
macrophages and effector T cells (Onuki et al., 2018). In
particular, activation of PPARγ by agonist treatment inhibits
the differentiation of IFN-γ-producing type 1 helper T (Th1) cells
by blocking the JAK–STAT signaling pathway (Natarajan and
Bright, 2002; Kanakasabai et al., 2010; Solt et al., 2012). Similarly,
activation of LXR inhibits the proliferation of T cells by
controlling sterol metabolism via induction of ATP-binding
cassette transporter G1 (ABCG1), which is involved in the
transmembrane transport of sterols (Bensinger et al., 2008).
NR4A1 deficiency is reported to expand the Th1 response
because activation of NR4A1 also limits the proliferation of
CD4+ T cells by controlling oxidative phosphorylation and
aerobic glycolysis (Liebmann et al., 2018). Furthermore,
treatment with a PXR agonist prevents the expansion of Th1
cells (Dubrac et al., 2010).
RXR agonists can activate these partner receptors
simultaneously, and therefore RXR was considered a
promising molecular target for inflammatory disorders.
Nonetheless, pre-existing RXR agonists have been reported to
induce various adverse effects, such as excess bodyweight gain,
hepatomegaly, hypothyroidism, and hypertriglyceridemia
(Standeven et al., 1997; Liu et al., 2002; de Vries-Van der Weij
et al., 2009). To address this issue, we recently developed NEt-3IB,
an RXR full agonist with lower lipophilicity compared with pre-
existing RXR agonists such as bexarotene (Figure 1A) (Kobayashi
et al., 2015). We demonstrated that NEt-3IB induces a low blood
concentration after oral administration. Furthermore, using
PET/CT imaging, we also observed that NEt-3IB exhibited
enterohepatic circulation upon intestinal absorption and was
delivered to the lower digestive tract (Kobayashi et al., 2015).
These pharmacokinetic properties of NEt-3IB may be beneficial
in avoiding systemic adverse effects and delivering the drug to the
lower intestine (Kakuta et al., 2012). In this study, we evaluated
the anti-inflammatory effects of NEt-3IB in an experimental CD
model induced by adoptive transfer of CD45RBhighCD4+ T cells
(Powrie et al., 1993). We report that NEt-3IB was persistent in the
intestinal lumen after oral administration and ameliorated the
wasting and colitis. This effect was attributed to the reduced
accumulation of Th1 cells in the colon.
MATERIALS AND METHODS
Chemical Reagents
Bexarotene and NEt-3IB were synthesized as described previously
(Boehm et al., 1994; Takamatsu et al., 2008).
Animals
ICR mice were purchased from Charles River Laboratories Japan
(Yokohama, Japan) and maintained under specific pathogen-free
(SPF) conditions at Okayama University, Okayama, Japan. C.B-
17-scid/scid and C.B-17+/+ mice were purchased from CLEA
Japan (Tokyo, Japan) and maintained under SPF conditions at
Keio University, Tokyo, Japan. Rag1−/− mice were bred and
maintained under SPF conditions at Keio University. C.B-17-
scid/scid and Rag1−/−mice were fed with CE-2 diet (CLEA Japan)
before T cell transfer and with MF diet (Oriental Yeast, Tokyo,
Japan) containing 0.015% NEt-3IB or regular MF after transfer.
Foxp3-hCD2 knock-in mice were bred and maintained under
SPF conditions at Keio University. C57BL6/J mice were
purchased from CLEA Japan. Foxp3-hCD2 knock-in mice and
C57BL6/J mice were fed with AIN-93G diet (Research Diet, New
Brunswick, NJ, United States) until their use in experiments at
6–12 weeks old. All animal experiments except for
pharmacokinetic studies were approved by the Animal Studies
Committees of Keio University.
Pharmacokinetic Studies
This experiment was conducted in accordance with the
Guidelines for Animal Experiments at Department of Animal
Resources, Advanced Science Research Center, Okayama
University, and all procedures were approved by the Animal
Care and Use Committee, Okayama University. The test
compounds were administered to 6-week-old ICR male mice
(n  5 per group). In the oral administration study, the test
compounds (10 mg/10 ml/kg) were suspended in 1% ethanol and
0.5% carboxymethyl cellulose (CMC) in distilled water and
administered by oral gavage. In the intravenous administration
study, the test compounds (1 mg/5 ml/kg) were dissolved in
saline containing 20% WellSolve (Celeste Corporation, Tokyo,
Japan) and administered via the tail vein. Blood samples
(approximately 0.6–1.0 ml each) were taken from the inferior
vena cava under isoflurane anesthesia at 0.5, 1, 3, 6, and 24 h after
administration. Then the animals were killed by cervical
dislocation. Brain, liver, kidney, bile, and large-intestinal
contents were immediately extirpated. Blood treated with
heparin in a centrifuge tube was centrifuged at 1,900 × g at
room temperature for 5 min. To 100 μl of the resulting plasma,
100 μl ice-cold 5.0 mM ammonium acetate solution (adjusted
with acetic acid to pH 5.0) and 1.0 ml ice-cold EtOAc were added.
The resulting mixture was vortexed for 30 s, kept at room
temperature for 10 min, and centrifuged at 1,900 ×g at room
temperature for 30 s. An 800 μl aliquot of the EtOAc phase was
removed and concentrated to dryness in a centrifugal evaporator.
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FIGURE 1 | Distribution of NEt-3IB after a single dosage to male mice. (A, B) Concentration of bexarotene or NEt-3IB in plasma and feces, respectively. Each
compound was orally administered at (A) 30 mg/kg and (B) 10 mg/kg. (C–F) Plasma, bile, liver, and kidney distribution of NEt-3IB after single administration at 1 mg/kg
(i.v.) and 10 mg/kg (p.o.). Circles and triangles show p.o. and i,v. data, respectively. Data shown are mean [n  5 (A, C–F) or 3 (B)] ± SD.
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The resulting residue was added to 100 μl acetonitrile. Brain, liver,
and kidney samples were homogenized in ice-cold EtOAc (500
µL/100 mg tissue) using a Cell Destroyer PS1000 (BMS, Tokyo,
Japan) and steel beads (for 5 mm) at 4,260 rpm for 60 s. Bile was
collected by washing out the gallbladder with 500 µl EtOAc. The
extract was vortexed for 30 s, kept under ultrasonic irradiation at
room temperature for 5 min, and centrifuged at 12,000 ×g at 4°C
for 10 min. A 200 μl aliquot of the EtOAc phase was collected and
concentrated to dryness in a centrifugal evaporator. The resulting
residue was dissolved by adding 100 μl acetonitrile. Each solution
was directly subjected to LC-MS/MS analysis, and the
concentration of each compound was determined from the
peak area of the sample with reference to a calibration plot
obtained with the authentic compound. All contents in the
large intestine were collected, and MeOH (1 ml) was added
under ultrasonic irradiation at room temperature for 20 min.
The resultant suspension was centrifuged at 1,500 ×g at 4°C for
20 min. An 800 μl aliquot of the MeOH phase was diluted 10-fold
with methanol. Each solution was directly subjected to High
Performance Liquid Chromatography (HPLC) analysis, and the
concentration of NEt-3IB was determined from the peak area of
the sample with reference to a calibration plot obtained with the
authentic compound.
Liquid Chromatography With Tandem Mass
Spectrometry
The API4000 LC-MS/MS system (Applied Biosystems, Toronto,
Canada) was used, consisting of an LC-20AD pump, an SPD-
20AV UV-Vis spectrophotometric detector, and a CTO-20AC
column oven (SHIMADZU, Kyoto, Japan) operating at 40°C. A
TSKgel ODS-100V column (2.0 i.d. × 50 mm, 3 μm; TOSOH,
Tokyo, Japan) was used. The mobile phase was acetonitrile/H2O 
65/35 containing 0.1% formic acid, v/v, and the flow rate was set at
0.2 ml/min.
High-Performance Liquid Chromatography
A Shimadzu liquid chromatographic system (Kyoto, Japan)
consisting of an LC-10AD pump, an SPD-10AV UV–vis
spectrophotometric detector, a CTO-10AS column oven, and a
C-R5A Chromatopac was used. An Inertsil ODS-3 column
(4.6 mm i.d. × 100 mm, 5 μm, GL Sciences, Tokyo, Japan)
with a guard column of Inertsil ODS-3 (4.6 mm i.d. × 10 mm,
5 μm, GL Sciences) was operated at 40°C. The mobile phase was
methanol/H2O  85/15 containing 0.1% formic acid, v/v. The
flow rate was set at 0.7 ml/min and the absorbance at 260 nm was
monitored.
Induction of Colitis by Adoptive Transfer of
CD4+ CD45RBhigh T Cells
Colitis was induced in C.B-17-scid/scid mice by adoptive transfer
of CD45RBhigh T cells. Mojosort Mouse CD 4 T Cell Isolation Kit
(BioLegend, San Diego, CA, United States) and biotin-conjugated
anti-mouse TER-119 (TER-119; BioLegend) were used to
negatively select CD4+ T cells of splenocytes from C.B-17+/+
mice. Negatively selected CD4+ T cells were labeled with Alexa
Fluor 647-conjugated anti-mouse CD4 (RM-4-5; BioLegend),
BV510-conjugated anti-mouse CD45 (30-F11; BioLegend), and
BV421-conjugated anti-mouse CD45RB (16A; BD Horizon, San
Jose, CA, United States). Dead cells were labeled with 7-
aminoactinomycin D (7-AAD) (BioLegend).
CD45+CD4+CD45RBhigh live T cells were isolated by FACS
Aria III (BD Biosciences San Jose, CA, United States). The
C.B-17-scid/scid recipients were each injected with 2 × 105
cells via the tail vein and transferred to conventional
conditions in the animal facilities at Keio University. Mice
were fed with 0.015% NEt-3IB-containing MF diet or control
MF diet for 7 weeks. The body weights of the mice were measured
every week, and the fecal diarrhea score was also measured from
week 4. The diarrhea score were assessed as follows: normal stool
(0), slightly soft (1), soft but formed (2), not formed (3), and
liquid stool (4) (Kjellev et al., 2006). The mice were humanely
killed at week 7.
Cell Preparation
Colonic lamina propria (LP) lymphocytes were obtained as
follows. Colon tissues were treated with 1 mM dithiothreitol
and 20 mM EDTA containing Hank’s Balanced Salt Solutions
(all from Nacalai-Tesque, Kyoto, Japan) for 20 min in a shaking
incubator (37°C, 200 rpm) to remove epithelial cells. After the
tissues were treated once more with 20 mM EDTA containing
Hank’s Balanced Salt Solution for 20 min, the tissues were then
minced and dissociated with Liberase solution containing 26
units/ml Liberase TM (Roche, Basel, Switzerland), 5 mg/ml
DNase I (Sigma Aldrich, St Louis, MO), 2% newborn calf
serum (Thermo Fisher Scientific, Waltham, MA,
United States), 100 μg/ml penicillin and streptomycin, and
20 mM HEPES in RPMI 1640 medium (all from Nacalai
Tesque) at 37°C for 30 min. The cell suspensions were then
filtered to obtain single-cell suspensions. Single-cell
suspensions from mesenteric lymph nodes (MLNs) was
prepared by mechanically crushing MLNs through 100 μm cell
strainers (Greiner Bio-One) in RPMI 1640 medium containing
2% newborn calf serum (Thermo Fisher Scientific).
For cell counts, cells were mixed with Precision Count Beads
(BioLegend), anti-mouse CD16/32 (93; BioLegend), eFluor 450-
conjugated anti-mouse CD45 (30-F11; Thermo Fisher Scientific),
and 7-aminoactinomycin D (7-AAD) (BioLegend) and were
analyzed by FACS Celesta and FlowJo software version 10 (BD
Biosciences).
Histology
Colonic tissue samples were fixed in Mildform (10%
formalin; Wako Pure Chemical Industries, Osaka, Japan)
overnight. After fixation, the samples were embedded in
paraffin using a Leica EG1160. Samples were cut into 5 µm
sections, deparaffinized and rehydrated, and then stained
with hematoxylin (Agilent Technologies, Inc., Santa Clara,
CA, United States) and eosin (Wako Pure Chemical
Industries, Osaka, Japan). Histological colitis scores were
reviewed by DT, who was blinded to each experiment. The
sections were scored for the presence of crypt abscesses (0–1),
the degree of thickness (0–3), and the degree of inflammatory
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infiltrate (0–3). The maximum score of the histological index
was 7.
Flow Cytometry
For inflammatory T cell analysis of the colitis model, the following
monoclonal antibodies were used: BV510-conjugated anti-mouse
CD45 (30-F11; BioLegend), redFluor 710-conjugated anti-mouse
CD4 (RM4-5; Tonbo Bioscience), BV605-conjugated anti-mouse
TCRβ (H57-597; BD Biosciences), BV650-conjugated anti-mouse
IFN-γ (XMG1.2; BD Horizon), and BV786-conjugated anti-mouse
IL-17A (TC11-18H10.1; BD Horizon). For Treg cell analysis of the
colitis model, the following monoclonal antibodies were used:
BV510-conjugated anti-mouse CD45 (30-F11; BioLegend),
redFluor-710-conjugated anti-mouse CD4 (RM4-5; Tonbo
Biosciences, San Diego, CA, United States), FITC-conjugated
anti-mouse TCRβ (H57-597; BD Biosciences), and eFluor 660-
conjugated anti-mouse Foxp3 (FJK-16s; ThermoFisher
Scientific). For macrophage analysis of the colitis model, the
following monoclonal antibodies were used: BV510-conjugated
anti-mouse CD45 (30-F11; BioLegend), Alexa Fluor 594-
conjugated anti-mouse CD3 (17A2; BioLegend), redFluor 710-
conjugated anti-mouse B220 (RA3-6B2; Tonbo Biosciences),
APC-conjugated anti-mouse Ly-6C (AL-21; BD Pharmagen,
San Jose, CA, United States), Alexa Fluor 488-conjugated anti-
mouse Ly-6G/Ly-6C (Gr-1; BioLegend), BUV737-conjugated
anti-mouse CD11b (M1/70; BD Horizon), BUV 395-
conjugated anti-mouse CD11c (HL3; BD Horizon), and
PerCP-Cy5.5-conjugated anti-mouse I-A/I-E (M5/114.15.2;
BioLegend). For in vitro T cell analysis, the following
monoclonal antibodies were used: BV510-conjugated anti-
mouse CD45 (30-F11; BioLegend), redFluor 710-conjugated
anti-mouse CD4 (RM4-5; Tonbo Biosciences), BUV737-
conjugated anti-mouse TCRβ (H57-597; BD Horizon), PerCP-
Cy5.5-conjugated anti-mouse IFN-γ (XMG1.2; BioLegend), PE-
conjugated anti-mouse/human T-bet (O4-46; BD Pharmagen),
and eFluor 660-conjugated anti-mouse Foxp3 (FJK-16s; Thermo
Fisher Scientific). Dead cells were labeled with Fixable Viability
Stain 780 (BD Biosciences). For intracellular cytokine and
transcription factor staining, LP lymphocytes and MLN
lymphocytes were cultured for 4 h in complete medium
(RPMI containing 10% MP Biomedicals, Santa Ana, CA,
United States: fetal bovine serum (FBS), Nacalai-Tesque
100 μg/ml penicillin and streptomycin, Thermo Fisher
Scientific 55 µM mercaptoethanol, and Nacalai-Tesque 20 mM
HEPES), and cultured T cells were cultured for 4 h in half-
complete medium (RPMI containing 5% FBS, 100 μg/ml
penicillin and streptomycin, 55 µM mercaptoethanol, and
20 mM HEPES), each supplemented with Cell Activation
Cocktail (BioLegend) and Protein Transport Inhibitor Cocktail
(Thermo Fisher Scientific). Lymphocytes and T cells were first
blocked with anti-CD16/32 and then stained with the
monoclonal antibodies described above. IC fixation buffer and
permeabilization buffer (Thermo Fisher Scientific) were used for
intracellular cytokine staining, and the Transcription Factor
Buffer Set (BD Pharmagen) was used for transcription factor
staining. For absolute cell counts, cells were mixed with Precision
Count Beads (BioLegend) and anti-mouse CD16/32 (93;
BioLegend) and stained with eFluor 450-conjugated anti-
mouse CD45 (30-F11; Thermo Fisher Scientific) and 7-AAD.
The stained samples were analyzed using an LSRII or a FACS
Celesta (BD Biosciences), and FlowJo software version 10.
In vitro Cultures
CD4+ T cells were enriched from splenocytes from C57BL6/J mice
or Foxp3-hCD2 knock-in mice by a negative selection method with
the BD iMag cell separation system, using biotin-conjugated
antibodies against mouse CD8α (53-6.7; Tonbo Biosciences),
CD11b (M1/70; BioLegend), CD11c (N418; Thermo Fisher
Scientific), B220 (RA3-6B2; BioLegend), Ly-6C/Ly6-G (Gr-1;
BioLegend), TER-119 (TER-119; BioLegend), and Streptavidin
Particle Plus (BD IMag). Negatively selected CD4+ T cells were
labeled with BV605-conjugated anti-mouse CD4 (RM4-5;
BioLegend), BV510-conjugated anti-mouse CD44 (IM4; BD
Horizon), redFluor 710-conjugated anti-mouse CD45 (30-F11;
Tonbo Biosciences), PE-Cy7-conjugated anti-CD25 (PC61.5;
Thermo Fisher Scientific), APC-eFluor 780-conjugated anti-
mouse NK 1.1 (PK136; Thermo Fisher Scientific), eFluor450-
conjugated anti-CD62L (MEL-14; Thermo Fisher Scientific), and
APC-conjugated anti-human CD2 (RPA-2.10; BioLegend). Dead
cells were labeled with 7-AAD (BioLegend).
CD45+CD4+CD62L+CD44−NK 1.1−Foxp3−(hCD2−) live naive
T cells were isolated by FACSAria III (BD Biosciences). In the
experiments described in Figure 4, 1×105 of CD4+ naive T cells were
cultured in advanced RPMI containing 5% FBS in the presence or
absence of NEt-3IB for 3–5 days. For the experiment using CellTrace
Violet (Thermo Fisher Scientific), T cells were incubated at 37°C for
20 min with CellTrace Violet before culture. T cells were polarized to
the Th1 subtype by the addition of 10 μg/ml anti-mouse IL-4 (Bio X
Cell, Lebanon, NH,United States) and 20 ng/ml recombinantmouse
IL-2 and IL-12 (BioLegend). The stained samples were analyzed
using FACS LSR II (BD Biosciences) and Flowjo software version 10.
Statistical Analysis
Statistical significance between two groups was calculated by
Student’s t-test or Welch’s t-test. In the in vitro study, statistical
significance between the control group and other groups was
calculated by Dunnet’s multiple comparison test or Dunn’s
multiple comparison test. p < 0.05 indicated statistical
significance. Data were output by Prism version 9 (GraphPad,
San Diego, CA, United States).
RESULTS
NEt-3IB has Low Systemic Transferability
and Reaches the Colon
To better understand the pharmacokinetics of NEt-3IB and
bexarotene (Figure 1A), another RXR agonist clinically used
for the treatment of cutaneous T cell lymphoma (Budgin
et al., 2005), we initially measured their concentrations in
plasma and feces after a single oral administration. The
plasma concentrations of NEt-3IB were much lower than
those of bexarotene at any timepoint (0.5–6 h post-
administration) (Figure 1B). Correspondingly, the delivery of
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NEt-3IB to the feces accumulated to approximately 60% of the
dosage, whereas that of bexarotene was less than 10% at 24 h post-
administration (Figure 1C). These data confirm that orally
administered NEt-3IB reaches the colon more efficiently
compared with bexarotene due to its low systemic transferability.
To further examine the systemic pharmacokinetics of NEt-3IB,
mice received intravenous (i.v.) injection (1mg/kg) and oral
administration (p.o.) (10mg/kg) of NEt-3IB. The concentrations
of NEt-3IB in plasma began to decline by 1 h after i.v. or 6 h after p.o.
administration, and reciprocally, the concentrations in the bile
increased at these time points (Figures 1D,E). On the basis of
these observations, we assumed that the livermay excrete NEt-3IB to
the intestinal tract via the bile duct. To test this assumption, we
measured the concentration of NEt-3IB in the liver and the kidney.
Although the concentration of NEt-3IB in the liver promptly
decreased, that in the bile gradually increased after i.v. injection
(Figure 1F). The hepatic concentration of NEt-3IB peaked
immediately after p.o. administration and then gradually declined
(Figure 1F). Conversely, NEt-3IB concentration in the kidney
rapidly decreased after i.v. administration and remained
consistently low after p.o. administration. Thus, NEt-3IB was
excreted to the bile in the liver rather than the kidney (Figure 1G).
NEt-3IB Treatment Alleviates T
Cell-dependent Colitis
We subsequently examined the anti-inflammatory effects of NEt-
3IB in an experimental colitis model induced by transferring
CD4+CD45RBhigh T cells into C.B-17-scid/scid mice and treating
with chow containing 0.015% NEt-3IB (approximately 30 mg/kg/
FIGURE 2 |NEt-3IB ameliorates T-cell-dependent experimental colitis. (A–H) Experimental colitis was induced by adoptive transfer of CD4+CD45RBhigh T cells into
C.B-17 scid/scid mice fed with control or NEt-3IB-containing diet for 7 weeks, and bodyweight loss (A) and diarrhea score (B) were observed. Data shown are the
average. Area under the curve of bodyweight change and fecal score. (C–F) Colon length, colon weight, and colon thickening were observed and measured in week 7.
Scale bar: 1 cm. (G) Colonic specimens were stained with hematoxylin and eosin (HE). (H) Histological scores of colonic specimens. (I) Total CD45+ cells in the
colon lamina propria of the CD4+ CD45RBhigh T cell transfer model. *p < 0.05, **p < 0.01.
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day) or with regular chow as a control. In the control group,
bodyweight gain was suppressed from 1-week post-transfer
onwards (Figure 2A). Meanwhile, the NEt-3IB-treated group
gained weight gradually over the course of the experiment,
suggesting that NEt-3IB alleviated wasting disease. Similarly,
NEt-3IB administration ameliorated diarrhea associated with
colitis, even though both groups exhibited only mild
symptoms (Figure 2B). Likewise, the colon weight and degree
of thickening (colon weight/length) were significantly lower in
the NEt-3IB group than that in the control group at 7 weeks after
cell transfer (Figures 2C–F). Histopathological examination also
showed massive infiltration of mononuclear cells in the colon of
the control group but not in the NEt-3IB group (Figure 2G).
Furthermore, the control group exhibited more severe crypt loss
and edema (Figures 2G,H). Flow cytometry confirmed the
massive infiltration of leukocytes in the colon lamina propria
(cLP) in the control group, whereas fewer inflammatory
infiltrates were observed in the NEt-3IB group (Figure 2I).
To further confirm the pharmacological effects of NEt-3IB, we
also evaluated the progressive bodyweight loss and diarrhea in a
similar colitis model using Rag1−/− mice as a recipient. The
control Rag1−/− recipients exhibited progressive body weight
loss in association with severe diarrhea. However, the
administration of NEt-3IB significantly mitigated the wasting
disease (Supplementary Figure S1A). Furthermore, NEt-3IB
improved colitis symptoms, namely, diarrhea, colon weight,
colonic wall thickening, crypt loss, and edema
(Supplementary Figures S1B–G). Collectively, these data
revealed an anti-inflammatory effect of NEt-3IB in the T cell-
dependent mouse colitis model.
NEt-3IB Suppressed the Accumulation of
Th1 Cells in the cLP
In the CD4+CD45RBhigh T-cell-transferred colitis model, IFN-
γ-producing effector T (Teff) cells including conventional T
helper 1 (Th1) cells and IFN-γ/IL-17-co-expressing T helper
17 (IFN-γ-producing Th17) cells are responsible for the
pathogenesis (Powrie et al., 1993; Sujino et al., 2011). To
determine whether NEt-3IB administration affects the
development of these Teff cell subsets, we analyzed T cell
profiles in the cLP and MLN of the colitis model at 7 weeks
post-transfer by flow cytometry after intracellular cytokine
staining. In the cLP, the numbers of Th1 cells, Th17 cells, and
IFN-γ-producing Th17 cells in the NEt-3IB group were less than
half that in the control group, although the frequencies of these
cells were comparable between the two groups (Supplementary
Figure S2A and Figure 3A). Moreover, Th1 and Th17 cells in the
MLN were significantly decreased in the NEt-3IB group
compared with the control group, and IFN-γ-producing Th17
cells also tended to be reduced. Of note, we also observed that the
number of Foxp3+ Treg cells was slightly but significantly
decreased in both the cLP and MLN of the NEt-3IB group
(Supplementary Figure S2B and Figure 3C). Colonic Teff
cell-derived IFN-γ activates macrophages to produce pro-
inflammatory cytokines that cause inflammation in the colon
(Stout and Bottomly, 1989). Considering that NEt-3IB treatment
reduced Th1 cells in the cLP in the colitis model, we analyzed the
colonic macrophages at 7 weeks post-transfer. We observed that
the total number of macrophages (CD11b+ Ly6G−Ly6C−CD11c−
MHC class II+) was decreased significantly in the NEt-3IB-treated
group compared with the control group (Supplementary Figure
S2C and Figure 3D). These data illustrated that NEt-3IB
diminishes colitis by inhibiting the accumulation of IFN-
γ-producing Teff cells and inflammatory macrophages in the
cLP and MLN.
NEt-3IB Inhibits the Differentiation and
Proliferation of Th1 Cells
We further investigated whether NEt-3IB has a direct impact on
the differentiation of Th cells using an in vitro culture system.
Sorted naïve CD4+ T cells were cultured under Th1-skewed
conditions for 5 days with or without NEt-3IB treatment
before flow cytometric analysis for the expression of Th1
markers (T-bet, IFN-γ), and a Treg marker (Foxp3). We
found that the frequencies of the T-bet+ and IFN-γ+ cells
decreased in the NEt-3IB-treated group in a dose-dependent
manner (Supplementary Figure S2D and Figure 4A).
Surprisingly, NEt-3IB treatment increased the proportion of
Foxp3+ T cells in a dose-dependent manner despite culture in
Th1 conditions (Supplementary Figure S2E and Figure 4B).
We subsequently examined whether NEt-3IB affected the
proliferation of Th1 cells in vitro. Fluorescent dye-labeled
naïve CD4+ T cells were cultured under Th1-differentiating
conditions for 5 days with or without Net-3IB treatment, and
then the dilution of CellTrace Violet was analyzed to detect
proliferating cells. NEt-3IB treatment significantly reduced the
frequency of proliferating cells in the T-bet+IFN-γ+ Th1
population when compared with the vehicle control
(Supplementary Figure S2F and Figure 4C). Together, these
data suggest that NEt-3IB directly inhibits both the
differentiation and proliferation of Th1 cells.
DISCUSSION
In this study, we demonstrated that NEt-3IB attenuated the
development of wasting disease and colitis in T cell-dependent
experimental colitis models by inhibiting the accumulation of
Th1 cells, which is the most dominant cell type contributing to
the pathogenesis of CD. Furthermore, our in vitro data revealed
that NEt-3IB directly inhibited the differentiation and expansion
of Th1 cells. NEt-3IB was designed to have lower lipophilicity
compared with conventional RXR agonists such as bexarotene
(Takamatsu et al., 2008; Kobayashi et al., 2015). We confirmed
that NEt-3IB exhibits a lower plasma concentration compared
with bexarotene after oral administration. In the detailed
pharmacokinetics analysis after i.v. administration, the
distribution to the liver represented approximately 49% of the
total dosage of NEt-3IB, while in the kidney there was only 12% of
the total dosage. Considering that the concentration of NEt-3IB
in bile rises after its peak in the liver, NEt-3IB is mostly likely to be
excreted efficiently to the bile. Notably, we observed that 60% of
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FIGURE 3 | NEt-3IB inhibits inflammatory T cells. (A) Frequency and cell number of IFN-γ-producing cells and IL-17A-producing cells in the colon lamina propria.
(B) Frequency and cell number of Th1 transcription factor T-bet and Th17 transcription factor RORγt-presenting cells of the colon lamina propria and mesenteric lymph
nodes. (C) Frequency and cell number of Foxp3+ regulatory T cells in the colon lamina propria and mesenteric lymph node of T cell-transferred SCID mice. (D)
Macrophages were gated as CD11b+Ly6G−Ly6C−CD11c−MHC2+. The right-hand graphs show the frequency of macrophages in CD45+ cells and the number of
macrophages. (A–D) are from CD45RBhigh T cell transfer model mice at 7 weeks post-transfer.
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the total dosage reached the colon within 24 h post-oral
administration, after the bile concentration peaked at 4 h.
These data support the enterohepatic circulation of NEt-3IB,
consistent with our previous report (Kobayashi et al., 2015). In
contrast, such enterohepatic circulation was not observed in
bexarotene, which was readily absorbed in the upper intestine
after oral administration with only a small portion delivered to
the colon. Thus, NEt-3IB is efficiently delivered to the colonic
lumen and should be translocated to the cLP under inflammatory
conditions, which are often associated with mucosal barrier
disruption.
Early studies showed that the activation and overexpression
of certain nuclear receptors exert anti-inflammatory effects. For
instance, PPAR agonists suppress the differentiation of Th1
cells in vitro by inhibiting the JAK–STAT signaling pathway
(Natarajan and Bright, 2002). LXR agonists also display similar
effects on the differentiation of Th1 cells (Solt et al., 2012).
Moreover, PPARγ and LXR agonists both suppress the
proliferation of T cells (Yang et al., 2000; Cunard et al.,
2002; Diab et al., 2004; Bensinger et al., 2008; Solt et al.,
2012). Given that these nuclear receptors heterodimerize
with RXR, and RXR agonists can activate these partner
nuclear receptors, the inhibitory effect of NEt-3IB on Th1
response may depend on the activation of LXR and PPAR
signaling. Additionally, PPARγ agonists inhibit IL-12
production by macrophages, which is important for the
differentiation and survival of Th1 cells (Natarajan and
Bright, 2002). Thus, NEt-3IB may directly and indirectly
suppress the Th1 response through the inhibition of IL-12
production by macrophages.
FIGURE 4 | NEt-3IB inhibits differentiation of inflammatory T cells and induces Foxp3+ cells in Th1 and Th17 conditions. (A, B) Naïve T cells were cultured in Th1
conditions, with or without NEt-3IB treatment for 5 days and analyzed for T-bet and IFN-γ expression (A), and for Foxp3 expression in the CD4+ T cell population (B). (C)
Naïve T cells were labeled with CellTrace Violet and cultured in Th1 conditions with or without NEt-3IB treatment for 5 days. Cultured cells were analyzed for their degree
of proliferation in the CD4+ T-bet+ IFN-γ+ population. *p < 0.05, **p < 0.01, ***p < 0.005.
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Our in vitro experiments demonstrated that Foxp3+ cells arose
in the NEt-3IB-treated group despite the Th1-differentiation
conditions. Given that RXR agonists modulate Foxp3+ Treg
cell differentiation (Takeuchi et al., 2013), NEt-3IB may drive
naïve CD4+ T cells to upregulate Foxp3 regardless of the culture
conditions. Because ectopic Foxp3 expression represses IFN-γ
expression, it is possible that NEt-3IB reduced the number of
Th1 cells in vitro by downregulating T-bet expression.
Nevertheless, in the CD4+CD45RBhigh T-cell-transfer colitis
model, no significant difference in the frequency of Treg cells
was identified between the control and NEt-3B-treated groups.
This observation implies that NEt-3IB may repress IFN-γ
expression via an unknown mechanism other than
upregulation of Foxp3. For instance, NEt-3IB may indirectly
dampen Th1 cell expansion by diminishing Th17 cell
differentiation. We observed a reduction in IFN-γ-producing
Th17 cells in the cLP of the NEt-3IB-treated group. This
transient cell population is generated from conventional
Th17 cells and further differentiates into Th1 cells (Sujino
et al., 2011; Basdeo et al., 2017). Therefore, the reduction in
IFN-γ-producing Th17 cells in the cLP of the NEt-3IB group
cells may lead to a decrease in Th1 cells. Notably, RXR and LXR
agonists negatively regulate the differentiation of Th17 cells
in vitro (Solt et al., 2012; Takeuchi et al., 2013). Thus, NEt-3IB
possibly restricted the development of Th17 cells in the colitis
model mice, resulting in the reduction of IFN-γ-producing
Th17, and in turn, Th17 cell-derived Th1 cells.
NEt-3IB treatment also reduced the number of macrophages.
NEt-3IB is likely to indirectly suppress the infiltration of
macrophages by inhibiting the expansion of IFN-γ-producing
Th17 and Th1 cells. Furthermore, NEt-3IB may directly
diminish macrophage activation. In support of this, we
previously found that a partial RXR agonist, CBT-PMN,
downregulates the production of pro-inflammatory cytokines
by bone marrow-derived macrophages (Onuki et al., 2018).
Furthermore, other groups showed that FXR agonist
treatment significantly downregulated IFN-γ-related gene
expression (Renga et al., 2009), and that PPAR and LXR
agonists also suppress the production of inflammatory
cytokines from macrophages (Birrell et al., 2007; Paukkeri
et al., 2013) Additionally, overexpression of NR4A1 and
NR4A2 in human macrophages inhibits pro-inflammatory
cytokines (Bonta et al., 2006). All these nuclear receptors
form heterodimers with RXR and are activated by RXR
agonists. These facts support the possibility that NEt-3IB
directly inhibits the activation and cytokine production of
macrophages by activating RXR partner nuclear receptors.
In conclusion, the present study demonstrated that NEt-3IB
ameliorated colitis by inhibiting both the expansion of Th1 cells
and the activation of inflammatory macrophages locally in the
colon. Our results indicate that NEt-3IB is a promising candidate
for IBD treatment as a small molecule inhibitor.
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